4 results match your criteria: "Heibei Yiling Hospital[Affiliation]"

Genetic Associations of Non-Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population.

J Invest Dermatol

July 2022

Research Unit of Dissecting the Population Genetics and Developing New Technologies for Treatment and Prevention of Skin Phenotypes and Dermatological Diseases (2019RU058), Chinese Academy of Medical Sciences, Beijing, China; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China; Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China; Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China. Electronic address:

View Article and Find Full Text PDF

Corrigendum: Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism.

Front Endocrinol (Lausanne)

September 2020

Department of Cardiovascularology, Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang, China.

[This corrects the article DOI: 10.3389/fendo.2020.

View Article and Find Full Text PDF

Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism.

Front Endocrinol (Lausanne)

May 2021

Department of Cardiovascularology, Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang, China.

Metabolic syndrome (MS) is a powerful risk factor for cardiovascular and cerebrovascular diseases. Although lifestyle intervention reduces several of the symptoms of the syndrome and cardiovascular risks, the lifestyle intervention that yields the benefits is restrictive. Jinlida is a Chinese patent medicine that has shown activity in type 2 diabetes, which has been approved in China.

View Article and Find Full Text PDF